Pipeline

ABL503

HomePipelineABL503

  • Pipeline
    ABL503
  • Program Target
    PD-L1 x 4-1BB
  • Disease Indication
    Solid Tumor
  • Development Stage
    Clinical Development
    (Phase 1)
Summary
ABL503 is a bispecific antibody that combines the capabilities of PD-L1 checkpoint pathway inhibiton with 4-1BB agonistic activity to overcome the specific limitations of PD-(L)1 immunotherapy and 4-1BB related toxicity. ABL503 is uniquely designed to only induce 4-1BB signalling when simultaneously binded to the PD-L1 tumor antigen on cancer cells, limiting the toxicity characteristic of traditional 4-1BB based treatment while augmenting T-cell activation. ABL503 shows superior anti-tumor activity in an animal model system compared to PD-L1 alone, 4-1BB alone, and the combination of PD-L1 and 4-1BB, with immunological memory resistant to any possible recurrence of the tumor.

Structure and Mechanism of Action

Structure and Mechanism of Action
좌우스크롤 Structure and Mechanism of Action

PD-L1 Dependent 4-1BB Activation

PD-L1 Dependent 4-1BB Activation
PD-L1 Dependent 4-1BB Activation

Superior Anti-Tumor Effect with Immunological Memory

Superior Anti-Tumor Effect with Immunological Memory
Superior Anti-Tumor Effect with Immunological Memory

Pharmacodynamic changes along with anti-tumor effect

Pharmacodynamic changes along with anti-tumor effect
Pharmacodynamic changes along with anti-tumor effect

Superior activity over Atezolizumab

Superior activity over Atezolizumab
Superior activity over Atezolizumab

Publications

좌우스크롤
Publications(Pipeline, Journal, Date, Title, Link, PDF)
Pipeline Journal Date Title Link PDF
ABL503 JITC 2021 Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade 링크정보 아이콘 PDF 아이콘

Posters

좌우스크롤
Posters(Pipeline, Name, Title, PDF)
Pipeline Name Title PDF
ABL503 SITC ABL503 (TJ-L14B), PD-L1×4-1BB bispecific antibody, induces superior anti-tumor activity by PD-L1-dependent 4-1BB activation with the increase of 4-1BB+CD8 + T cells in tumor microenvironment PDF 아이콘
PEGS 2019 The PD-L1 x 4-1BB Bispecific Antibody ABL503 Shows Potent Anti-Tumor Effect through Tumor-Directed T Cell Activation PDF 아이콘